Hrt Financial LP Krystal Biotech, Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$108.01 - $179.35 $1.55 Million - $2.57 Million	-14,350 Reduced 62.7%	8,536 $1.52 Million
Q4 2023 Feb 09, 2024	BUY	$96.0 - $128.29 $2.2 Million - $2.94 Million	22,886 New	22,886 $2.84 Million
Q4 2022 Feb 10, 2023	BUY	$63.14 - $79.9 $359,519 - $454,950	5,694 New	5,694 $451,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $629,598 - $873,252	-12,110 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $482,099 - $1.07 Million	12,110 New	12,110 $847,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.